¼¼°èÀÇ BNP ¹× NT-proBNP ½ÃÀå : ºÎ¹®º°, ±¹°¡ ¹× Áö¿ªº° »ê¾÷ ºÐ¼®(2024-2032³â) - ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø
BNP and NTproBNP Market, By Type, By Application, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1514884
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 399 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,539,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,495,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,892,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

BNP ¹× NT-proBNP(BNP and NTproBNP) ½ÃÀå ±Ô¸ð´Â 2023³â 16¾ï 8,750¸¸ ´Þ·¯¿´À¸¸ç, 2024³âºÎÅÍ 2032³â±îÁö CAGR 12.5%·Î ÃßÀÌÇϸç È®´ë ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

BNP ¹× NT-proBNP ½ÃÀå-½ÃÀå ¿ªÇÐ

BNP ¹× NT-proBNP ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

BNP ¹× NT-proBNP ¹ÙÀÌ¿À¸¶Ä¿ ¼ö¿ä´Â Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀǽÄÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Áõ°¡ÇÏ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÉÀåÇùȸÀÇ º¸°í¿¡ µû¸£¸é ½ÉºÎÀüÀº ¹Ì±¹¿¡¼­ ¾à 620¸¸ ¸íÀÇ ¼ºÀο¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç Áø´Ü µµ±¸ °³¼±ÀÌ ½Ã±ÞÇÏ´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ Áúº´ ¿¹¹æ °ü¸® ¼¾ÅÍ(CDC)´Â ½ÉÀå °ü·Ã Áúº´ °ü¸®¿¡¼­ Á¶±â ¹ß°ßÀÇ Á߿伺À» °­Á¶Çϰí Àû½Ã °³ÀÔÀ» ÃËÁøÇÏ¸ç °Ç°­ °ü¸® ºñ¿ëÀ» ÁÙÀÌ´Â ¹ÙÀÌ¿À ¸¶Ä¿ °Ë»çÀÇ ¿ªÇÒÀ» °­Á¶ÇÕ´Ï´Ù. Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¹¹æÀÇ·áÀü·«À» ÃßÁøÇÏ´Â ¼¼°èº¸°Ç±â±¸(WHO)¿Í °°Àº Á¶Á÷¿¡ ÀÇÇÑ ÀÌ´Ï¼ÅÆ¼ºê´Â ½ÉÇ÷°ü Áúȯ °ü¸®¿¡ À־ Áß¿äÇÑ µµ±¸·Î¼­ BNP ¹× NT-proBNP ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Ã¤Åà Ȯ´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

BNP ¹× NT-proBNP ½ÃÀå-ÁÖ¿ä ÅëÂû·Â

¿ì¸®ÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 12.5%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À¯Çüº°·Î NTproBNP´Â 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸¿©ÁÙ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ëµµº°·Î´Â 2023³â¿¡ ½ÉºÎÀü Áø´ÜÀÌ ÁÖ¿ä À¯ÇüÀÌ µË´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì¿Í À¯·´ÀÌ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀÌ µË´Ï´Ù.

BNP ¹× NT-proBNP ½ÃÀå-¼¼ºÐÈ­ ºÐ¼® :

¼¼°èÀÇ BNP ¹× NT-proBNP ½ÃÀåÀº À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº À¯Çü¿¡ µû¶ó µÎ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. N ¸»´Ü ÇÁ·Î BÇü ³ªÆ®·ý ÀÌ´¢ ÆéƼµå(NTproBNP)´Â BÇü ³ªÆ®·ý ÀÌ´¢ ÆéƼµå(BNP)¿¡ ºñÇØ ÀÓ»ó ÀÀ¿ë ¹üÀ§°¡ ³Ð°í ¾ÈÁ¤¼ºÀÌ ³ô±â ¶§¹®¿¡ Áö¹èÀûÀÎ ÁöÀ§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. NTproBNP´Â Ź¿ùÇÑ Áø´Ü Á¤È®¼º°ú ½ÉÇ÷°ü Áúȯ °ü¸®ÀÇ ¿¹ÈÄÀû °¡Ä¡¿¡ ÀÇÇØ Á¡Á¡ ´õ ÁöÁöµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¿ëµµ¿¡ µû¶ó ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ½ÉºÎÀü Áø´Ü, ½ÉÇ÷°ü Áúȯ °ü¸®, ½ÅºÎÀü Áø´Ü. ½ÉÇ÷°ü Áúȯ °ü¸®´Â ½ÉÀå°ú °ü·ÃµÈ Áúº´ÀÇ À¯º´·ü Áõ°¡¿Í ¿¹ÈÄ ¹× Ä¡·á ¸ð´ÏÅ͸µ¿¡¼­ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» µÞ¹ÞħÇϸç ÁÖ¿ä ÀÀ¿ë ºÐ¾ß·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ½ÉºÎÀü Áø´ÜÀÌ À̾îÁö°í, ȯÀÚÀÇ ¿¹ÈÄ °³¼±¿¡¼­ Á¶±â ¹ß°ß°ú °³ÀÔÀÇ Á߿伺ÀÌ °­Á¶µÇ¾ú½À´Ï´Ù.

BNP ¹× NT-proBNP ½ÃÀå-Áö¸®Àû ÅëÂû

ºÏ¹Ì¿Í À¯·´°ú °°Àº ½ÅÈï °æÁ¦ ±¹°¡µéÀº °Ç°­ °ü¸® ÀÎÇÁ¶ó°¡ È®¸³µÇ¾úÀ¸¸ç ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·üÀÌ ³ô±â ¶§¹®¿¡ ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì¿¡¼­´Â ÷´Ü Áø´Ü ±â¼ú°ú dzºÎÇÑ È¯ÀÚ ¼ö¸¦ ÀÚ¶ûÇÏ´Â ¹Ì±¹ÀÌ ¿ìÀ§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. À¯·´µµ ÀÌ¿¡ ÀÌ¾î µ¶ÀÏÀ̳ª ¿µ±¹°ú °°Àº ±¹°¡µéÀÌ È°¹ßÇÑ R&D Ȱµ¿À» ÅëÇØ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí ¾Æ½Ã¾Æ ÅÂÆò¾çÀº Áß±¹À̳ª Àεµ¿Í °°Àº ±¹°¡¿¡¼­ ½ÉºÎÀü ¹ßº´·üÀÌ »ó½ÂÇϰí ÀÇ·á ÁöÃâÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ Å« ¼ºÀåÀÌ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ³²¹Ì¿Í Áßµ¿ÀÇ ½ÅÈï ±¹°¡µéµµ ½ÉÇ÷°ü Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ Çâ»óµÇ°í °Ç°­ °ü¸® ½Ã½ºÅÛÀÌ ¹ßÀüÇÔ¿¡ µû¶ó BNP ¹× NT-proBNP ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù.

BNP ¹× NT-proBNP ½ÃÀå-°æÀï ±¸µµ :

BNP ¹× NT-proBNP ½ÃÀå °æÀï ±¸µµ¿¡¼­ Roche Diagnostics, Abbott Laboratories ¹× Siemens Healthineers¿Í °°Àº ÁÖ¿ä ±â¾÷Àº ±¤¹üÀ§ÇÑ Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í °­·ÂÇÑ ÆÇ¸Å ³×Æ®¿öÅ©¸¦ Ȱ¿ëÇÏ¿© ¿ìÀ§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®ÀÇ °¨µµ¿Í ƯÀ̼ºÀ» ³ôÀ̱â À§ÇØ Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å¿¡ ÁÖ·ÂÇÏ°í °æÀï·ÂÀ» À¯ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü ¹× ¿¬±¸ ±â°ü°úÀÇ Àü·«Àû Á¦ÈÞ ¹× ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ½ÃÀå ¸®´õ´Â ÇöÀçÀÇ ÀÔÁö¸¦ È®´ëÇÏ°í »õ·Î¿î ½ÃÀå¿¡ ´ëÇÑ ¾×¼¼½º¸¦ ¾ò°í ÀÖ½À´Ï´Ù. ½ÅÈï±â¾÷Àº ¶ÇÇÑ ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç Ç÷§ÆûÀ» µµÀÔÇÏ°í ½ÃÀå ³» Æ´»õ ºÎ¹®À» Ÿ°ÙÆÃÇÔÀ¸·Î½á Å©°Ô ¾àÁøÇϰí ÀÖ½À´Ï´Ù. Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó °æÀïÀÌ Ä¡¿­ ÇØÁö°í °¢ ȸ»ç´Â ÁøÈ­ÇÏ´Â °í°´ ¿ä±¸¿Í ±ÔÁ¦ ¿ä±¸ »çÇ׿¡ È¿°úÀûÀ¸·Î ´ëÀÀÇϱâ À§ÇØ R&D¿¡ ÅõÀÚÇØ¾ßÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå BNP ¹× NT-proBNP ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå BNP ¹× NT-proBNPÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå BNP ¹× NT-proBNP »ê¾÷ Á¶»ç

Á¦5Àå BNP ¹× NT-proBNP ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå BNP ¹× NT-proBNP ½ÃÀå »óȲ

Á¦7Àå BNP ¹× NT-proBNP ½ÃÀå-À¯Çüº°

Á¦8Àå BNP ¹× NT-proBNP ½ÃÀå-¿ëµµº°

Á¦9Àå BNP ¹× NT-proBNP ½ÃÀå-ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå BNP ¹× NT-proBNP ½ÃÀå-Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼®-BNP ¹× NT-proBNP »ê¾÷

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

BNP and NTproBNP Market size was valued at USD 1,687.5 Million in 2023, expanding at a CAGR of 12.5% from 2024 to 2032.

The BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-brain Natriuretic Peptide) Market encompasses diagnostic tests measuring biomarkers associated with heart failure, aiding in diagnosis, prognosis, and treatment monitoring. The increasing prevalence of cardiovascular diseases, the aging population, and advancements in diagnostic technologies, facilitating accurate and early detection of heart failure are driving the market growth. However, restraints include high costs associated with testing and limited accessibility to healthcare services in certain regions. Nonetheless, opportunities lie in the development of point-of-care testing solutions, expanding healthcare infrastructure in emerging markets, and ongoing research into novel biomarkers for improved heart failure management.

BNP and NTproBNP Market- Market Dynamics

Growing demand for BNP and NTproBNP biomarkers is fueled by increased awareness of early disease detection

The demand for BNP and NTproBNP biomarkers is on the rise, propelled by heightened awareness of early disease detection. According to a report by the American Heart Association, heart failure affects approximately 6.2 million adults in the United States, underscoring the urgent need for improved diagnostic tools. Furthermore, the Centers for Disease Control and Prevention (CDC) highlights the importance of early detection in managing heart-related conditions, emphasizing the role of biomarker testing in facilitating timely interventions and reducing healthcare costs. Moreover, initiatives by organizations like the World Health Organization (WHO) to promote preventive healthcare strategies contribute to the growing adoption of BNP and NTproBNP biomarkers as vital tools in cardiovascular disease management.

BNP and NTproBNP Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.5% over the forecast period (2024-2032)

Based on Type segmentation, NTproBNP was predicted to show maximum market share in the year 2023

Based on application segmentation, Heart failure diagnosis was the leading type in 2023

Based on region, North America and Europe was the leading revenue generator in 2023

BNP and NTproBNP Market- Segmentation Analysis:

The Global BNP and NTproBNP Market is segmented based on Type, Application, End-User, and Region.

The market is divided into two categories based on Type: B-type Natriuretic Peptide and N-terminal pro-B-type Natriuretic Peptide. N-terminal pro-B-type Natriuretic Peptide (NTproBNP) holds the dominant position, driven by its wider range of clinical applications and higher stability compared to B-type Natriuretic Peptide (BNP). NTproBNP is increasingly favored for its superior diagnostic accuracy and prognostic value in cardiovascular disease management.

The market is divided into three categories based on application: Heart Failure Diagnosis, Cardiovascular Disease Management, and Renal Failure Diagnosis. Cardiovascular disease management emerges as the primary application segment, fueled by the increasing prevalence of heart-related conditions and the pivotal role of biomarkers in prognosis and treatment monitoring. Heart failure diagnosis follows closely, emphasizing the importance of early detection and intervention in improving patient outcomes.

BNP and NTproBNP Market- Geographical Insights

Developed economies such as North America and Europe lead the market due to their well-established healthcare infrastructure and high prevalence of cardiovascular diseases. In North America, the United States dominates with advanced diagnostic technologies and a large patient pool. Europe follows suit, with countries like Germany and the UK driving market growth through robust research and development activities. Meanwhile, the Asia-Pacific region is poised for substantial growth, attributed to the rising incidence of heart failure and increasing healthcare spending in countries like China and India. Emerging economies in Latin America and the Middle East are also witnessing a surge in demand for BNP and NTproBNP biomarkers as awareness of cardiovascular diseases improves and healthcare systems evolve.

BNP and NTproBNP Market- Competitive Landscape:

In the competitive landscape of the BNP and NTproBNP markets, key players such as Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers dominate, leveraging their extensive product portfolios and strong distribution networks. These companies focus on continuous innovation to enhance the sensitivity and specificity of biomarker assays, thereby maintaining their competitive edge. Additionally, strategic collaborations and partnerships with healthcare providers and research institutions enable market leaders to expand their presence and gain access to new markets. Emerging players are also making significant strides by introducing novel biomarker testing platforms and targeting niche segments within the market. As the demand for early disease detection grows, competition intensifies, prompting companies to invest in research and development to address evolving customer needs and regulatory requirements effectively.

Recent Developments:

In September 2022, SRL Diagnostics introduced "Heart Assure," a specialized test designed to predict an individual's risk of cardiac incidents. Utilizing a high-sensitivity troponin blood test, provides an accurate heart health risk score, forecasting potential cardiac damage.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BNP AND NTPROBNP MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Abbott Laboratories

Biomerieux SA

Bio-Rad Laboratories, Inc.

Danaher Corporation

DiaSorin S.p.A

Fujirebio Diagnostics, Inc.

LSI Medience Corporation

Ortho Clinical Diagnostics

Randox Laboratories Ltd.

Response Biomedical Corp.

Roche Diagnostics

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

Siemens Healthineers AG

Thermo Fisher Scientific, Inc.

Tosoh Corporation

Others

GLOBAL BNP AND NTPROBNP MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL BNP AND NTPROBNP MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL BNP AND NTPROBNP MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL BNP AND NTPROBNP MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. BNP and NTproBNP Market Overview

2. Executive Summary

3. BNP and NTproBNP Key Market Trends

4. BNP and NTproBNP Industry Study

5. BNP and NTproBNP Market: COVID-19 Impact Analysis

6. BNP and NTproBNP Market Landscape

7. BNP and NTproBNP Market - By Type

8. BNP and NTproBNP Market - By Application

9. BNP and NTproBNP Market - By End-User

10. BNP and NTproBNP Market- By Geography

11. Key Vendor Analysis- BNP and NTproBNP Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â